cro.directory
← Compare landing

Aragen Life Sciences vs uBriGene

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/aragen/ubrigene

CategoryAragen Life SciencesuBriGene
Listed sitecroboth
SummaryGlobal CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.uBriGene is a global leader in advanced therapy medicinal products (ATMPs), cell and gene therapy CDMO services, and analytical testing. Headquartered in Maryland with operations across North America and Asia, the company specializes in bridging ATMP concepts from early…
Services
  • Discovery Research
  • Target Identification & Validation
  • High-Throughput Screening
  • Medicinal Chemistry
  • Computational & In-Silico Drug Discovery
  • Protein Engineering
  • In Vitro Pharmacology
  • In Vitro ADME / DMPK
  • Safety Pharmacology
  • Genetic Toxicology
  • Preclinical In Vitro Studies
  • Preclinical In Vivo Studies
  • In Vivo Efficacy Models
  • In Vivo PK / PD Studies
  • GLP Toxicology
  • Carcinogenicity Studies
  • DART (Reproductive & Developmental Toxicology)
  • Specialized & Large-Animal Models
  • Bioanalysis
  • LC-MS Bioanalysis (Small Molecule)
  • Ligand-Binding Bioanalysis (Large Molecule)
  • Immunogenicity Assays (ADA / NAb)
  • Biomarker Assays
  • Flow Cytometry Services
  • Analytical Method Development & Validation
  • ICH Stability Studies
  • Translational Research
  • US FDA Regulatory Strategy
  • EU EMA Regulatory Strategy
  • Japan PMDA Regulatory Strategy
  • China NMPA Regulatory Strategy
  • Regulatory Affairs
  • Analytical Method Development & Validation
  • US FDA Regulatory Strategy
  • EU EMA Regulatory Strategy
  • China NMPA Regulatory Strategy
  • Translational Research
Modalities
  • Small Molecule
  • Biologics (Monoclonal Antibodies)
  • Biologics (Other)
  • Antibody-Drug Conjugate (ADC)
  • Oligonucleotide
  • mRNA
  • Cell Therapy
  • Gene Therapy
  • Peptide
  • Vaccine
  • mRNA
  • Cell Therapy
  • Gene Therapy
  • AAV / Viral Vector Platform
Indications
  • Oncology
  • Immunology
  • Neurology
  • Psychiatry
  • Metabolic
  • Cardiovascular
  • Infectious Disease
  • Rare Disease
  • Respiratory
  • Dermatology
  • Ophthalmology
  • Gastroenterology
  • Nephrology
  • Women's Health
  • Oncology
Locations
  • Global Headquarters, Hyderabad, Telangana, India
  • R&D and Manufacturing Campus, Hyderabad, Telangana, India
  • R&D Campus, Hyderabad, Telangana, India
  • Manufacturing Campus, Visakhapatnam, Andhra Pradesh, India
  • R&D Campus, Bengaluru, Karnataka, India
  • Biosafety Solutions, Pune, Maharashtra, India
  • Regional Office, New Delhi, Delhi, India
  • Sales Office, Tokyo, Japan
  • Sales Office, Seoul, South Korea
  • Sales Office, Cambridge, Massachusetts, USA
  • R&D Campus, Morgan Hill, California, USA
  • Sales Office, Utrecht, Netherlands
  • Sales Office, Milan, Italy
  • Sales Office, South Korea
  • Global Headquarters & R&D and Manufacturing Campus, Hyderabad, Telangana, India
  • R&D Campus, Pune, Maharashtra, India
  • R&D Campus, New Delhi, Delhi, India
  • Sales Office, New Jersey, New Jersey, USA
  • Global Headquarters, R&D and Manufacturing Campus, Hyderabad, Telangana, India
  • R&D Campus, Mallapur, Hyderabad, India
  • Headquarters, Maryland, Maryland, USA
  • Boston, Boston, Massachusetts, USA
  • Worcester, Worcester, Massachusetts, USA
Certifications
  • USFDA · Identifier: EIR for Nacharam Unit 1
  • FDA · Identifier: 20+ INDs filed and accepted
  • EMA · Identifier: 20+ INDs filed and accepted
  • NMPA · Identifier: 20+ INDs filed and accepted
ReviewsReview summary appears after site-level review signal gate opens.Review summary appears after site-level review signal gate opens.